| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2007.
MEMO TO THE MEDIA |
Press Release
BRCA2 Carriers At Increased Risk for Deadly Form of Prostate Cancer
jncimedia{at}oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Carriers of a BRCA2 variation specific to Iceland are more likely to develop aggressive and lethal prostate cancer than noncarriers, according to a study published online June 12 in the Journal of the National Cancer Institute.
Mutations in the BRCA2 gene are associated with increased prostate cancer risk, but it has been unclear whether they are related to progression of the disease.
Laufey Tryggvadóttir of the Icelandic Cancer Registry and colleagues compared survival and disease progression in prostate cancer patients with the Icelandic BRCA2 999del5 founder mutation and those without the mutation. Using a pool of male relatives of women with breast cancer, researchers identified prostate cancer patients diagnosed in Iceland between 1955 and 2004. The mutation was present in 30 patients (5.7%).
The mutation's carriers were younger at the time of diagnosis and had more advanced staged cancer, higher-grade tumors, and shorter median survival time (2.1 years vs. 12.4 years) compared with noncarriers.
The authors conclude that "it is of great importance to study whether these results can be confirmed for carriers of mutations at other locations within the BRCA2 gene. Finally, the results indicate that in the search for new methods to predict prostate cancer progression, it may be fruitful to look for gene or protein expression patterns in prostate cancers resembling the patterns seen in BRCA2 mutation carriers."
In an accompanying editorial, Sholom Wacholder, Ph.D., of the National Cancer Institute in Bethesda, Md., and colleagues discuss the limitations of this study and other similar studies—the small number of mutation carriers, changes in screening practices, and the assumption that the date of diagnosis corresponds with the time of disease onset.
"This work may clarify when and how BRCA2 mutations alter carcinogenesis. More generally, it offers an avenue for improving the accuracy of information available to patients when they are diagnosed with cancer. Nonetheless, the immediate clinical utility of these findings is limited, despite unusually rigorous design and analysis," the authors write.
###
Contact:
- Article: Laufey Tryggvadóttir, +354 690 3766, laufeyt{at}krabb.is
- Editorial: National Cancer Institute Press Office, 301-496-6641, ncipressofficers{at}mail.nih.gov
Citations:
- Article: Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, et al. Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers. J Natl Cancer Inst 2007; 99: 929–935
- Editorial: Wacholder S, Loukissas JK, Hartge P. Studies of Genes and Cancer Survival: Pieces of the Puzzle. J Natl Cancer Inst 2007; 99: 908–909
Note to Reporters:
Beginning with this issue, the Journal of the National Cancer Institute will publish an early online edition of our journal, and we are changing our embargo date accordingly. JNCI will now be published online the second and last Wednesday of every month. In the near future, we will publish papers online weekly, though the day of the week and embargo time for our releases will remain the same.
Embargoed press releases and the accompanying copies of JNCI's original research papers are posted to EurekAlert the Thursday before online publication at www.eurekalert.org/jrnls/jnci/. The embargo time will remain Tuesdays at 4 p.m. EST.
We may also be starting up an e-mail list to alert reporters when papers are available on the EurekAlert site. If you would be interested on being on this list, please let us know at jncimedia{at}oxfordjournals.org. The content will continue to be available through EurekAlert's e-mail system and our EurekAlert page.
If you have any questions or concerns, please contact Andrea Widener, news editor, at andrea.widener{at}oxfordjournals.org or 301-841-1286.
The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jnci.oxfordjournals.org/.
Related Articles in JNCI
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 929-935.
J Natl Cancer Inst 2007 99: 908-909.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||